0000899243-16-028310.txt : 20160831
0000899243-16-028310.hdr.sgml : 20160831
20160831182336
ACCESSION NUMBER: 0000899243-16-028310
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20160829
FILED AS OF DATE: 20160831
DATE AS OF CHANGE: 20160831
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Sagent Pharmaceuticals, Inc.
CENTRAL INDEX KEY: 0001369786
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 1901 NORTH ROSELLE ROAD, SUITE 700
CITY: SCHAUMBURG
STATE: IL
ZIP: 60195
BUSINESS PHONE: 847-908-1604
MAIL ADDRESS:
STREET 1: 1901 NORTH ROSELLE ROAD, SUITE 700
CITY: SCHAUMBURG
STATE: IL
ZIP: 60195
FORMER COMPANY:
FORMER CONFORMED NAME: Sagent Holding Co.
DATE OF NAME CHANGE: 20090529
FORMER COMPANY:
FORMER CONFORMED NAME: NHS PHARMACEUTICALS
DATE OF NAME CHANGE: 20060720
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Behrens Mary Taylor
CENTRAL INDEX KEY: 0001309855
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-35144
FILM NUMBER: 161864186
MAIL ADDRESS:
STREET 1: C/O SAGENT PHARMACEUTICALS, INC.
STREET 2: 1901 NORTH ROSELLE ROAD, SUITE 700
CITY: SCHAUMBURG
STATE: IL
ZIP: 60195
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2016-08-29
1
0001369786
Sagent Pharmaceuticals, Inc.
SGNT
0001309855
Behrens Mary Taylor
C/O SAGENT PHARMACEUTICALS, INC.
1901 NORTH ROSELLE ROAD, SUITE 700
SCHAUMBURG
IL
60195
1
0
0
0
Common Stock
2016-08-29
4
U
0
7097
21.75
D
0
D
Restricted Stock Units
2016-08-29
4
D
0
8556
21.75
D
Common Stock
8556
0
D
Restricted Stock Units
2016-08-29
4
D
0
691
21.75
D
Common Stock
691
0
D
Restricted Stock Units
2016-08-29
4
D
0
1381
21.75
D
Common Stock
1381
0
D
Restricted Stock Units
2016-08-29
4
D
0
1860
21.75
D
Common Stock
1860
0
D
Restricted Stock Units
2016-08-29
4
D
0
760
21.75
D
Common Stock
760
0
D
Stock Option to Buy
11.60
2016-08-29
4
D
0
6379
10.15
D
2020-12-02
Common Stock
6379
0
D
Pursuant to the Agreement and Plan of Merger by and among Nichi-Iko Pharmaceutical Co. Ltd., Shepard Vision, Inc. and Sagent Pharmaceuticals, Inc. (the "Merger Agreement"), these shares were disposed of in a cash tender offer by Shepard Vision, Inc. to acquire common stock of Sagent Pharmaceuticals, Inc. in exchange for $21.75 per share in cash, without interest, less any applicable withholding taxes (the "Consideration").
Each restricted stock unit represents a contingent right to receive one share of SGNT common stock.
The restricted stock units provided for vesting on February 22, 2017.
Each restricted stock unit was disposed pursuant to the Merger Agreement whereby each such restricted stock unit was cancelled and converted into the right to receive the Consideration.
The restricted stock units provided for vesting in four equal annual installments beginning on April 9, 2016.
The restricted stock units provided for vesting in four equal annual installments beginning on February 25, 2016.
The restricted stock units provided for vesting in four equal annual installments beginning on February 18, 2015.
The restricted stock units provided for vesting in four equal annual installments beginning on February 21, 2014.
Represents the disposition of options, which provided for vesting in four equal installments beginning December 2, 2011. The options were cancelled pursuant to the Merger Agreement in exchange for a cash payment of $10.15 per share subject to the option. This per share price represents the difference between the applicable exercise price of the option and the Consideration.
/s/ Mary Taylor Behrens
2016-08-31